Global Fatty Liver Treatment Market Insights Forecasts to 2033

• The Global Fatty Liver Treatment Market Size was Valued at USD 21.55 Billion in 2023
• The Market Size is Growing at a CAGR of 5.19% from 2023 to 2033
• The Worldwide Fatty Liver Treatment Market Size is Expected to Reach USD 35.76 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Fatty Liver Treatment Market Size is Anticipated to Exceed USD 35.76 Billion by 2033, Growing at a CAGR of 5.19% from 2023 to 2033.

Market Overview

Fatty liver, or hepatic steatosis, is the buildup of excess fat in the liver, often linked to obesity, alcohol use, or metabolic disorders. The disease mainly consists of two types alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD). The fatty liver treatment market is growing rapidly, driven by the increasing prevalence of obesity, diabetes, and sedentary lifestyles worldwide. This market includes lifestyle management programs, pharmacological treatments, supplements, and medical devices aimed at controlling liver fat buildup and preventing complications like cirrhosis or liver cancer. Key players include pharmaceutical companies developing drugs for NAFLD and NASH (non-alcoholic steatohepatitis), with research into new therapies like anti-fibrotic drugs and metabolic modulators expanding the market.

Report Coverage

This research report categorizes the market for the global fatty liver treatment based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global fatty liver treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global fatty liver treatment market.

Driving Factors

The driving factors for fatty liver treatment include the increasing global prevalence of obesity, type 2 diabetes, and metabolic syndrome, which are closely linked to non-alcoholic fatty liver disease (NAFLD). Increased alcohol consumption is a key factor in alcoholic fatty liver disease (AFLD). Awareness of liver-related health risks, advances in diagnostic technologies, and research into novel therapies fuel demand for effective treatments. Changes in dietary habits and sedentary lifestyles also contribute to the need for lifestyle interventions and pharmacological solutions.

Restraining Factors

The restraining factors for fatty liver treatment include the lack of approved therapies, early diagnosis challenges, high costs of advanced diagnostics and emerging therapies, low patient adherence to lifestyle changes, the complex multifactorial nature of fatty liver disease, and regulatory hurdles. These factors limit treatment options, especially in low and middle-income regions, which hinders the development of effective treatments.

Market Segmentation

The global fatty liver treatment market share is classified into type, diagnosis, and treatment.

• The non-alcoholic steatohepatitis segment is expected to hold the largest share of the global fatty liver treatment market during the forecast period.   

Based on the type, the global fatty liver treatment market is divided into non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and alcoholic fatty liver disease. Among these, the non-alcoholic steatohepatitis segment is expected to hold the largest share of the global fatty liver treatment market during the forecast period. The non-alcoholic steatohepatitis (NASH) segment is expected to grow in the fatty liver treatment market due to its severe form, which can lead to liver damage and cancer. The growing prevalence of obesity, diabetes, and metabolic syndrome is driving NASH cases globally. Pharmaceutical companies are investing in research and development of new therapies, particularly anti-fibrotic drugs and metabolic modulators, to address this unmet medical need.

• The imaging segment is expected to grow at the fastest CAGR in the global fatty liver treatment market during the forecast period.   

Based on the diagnosis, the global fatty liver treatment market is divided into imaging, liver biopsy, and blood tests. Among these, the imaging segment is expected to grow at the fastest CAGR in the global fatty liver treatment market during the forecast period. The imaging segment which consists of non-invasive techniques like ultrasound, MRI, and FibroScan, is expected to grow in the fatty liver treatment market due to their safety, accuracy, and ease of use. With the increasing prevalence of NAFLD and NASH, the demand for reliable diagnostic tools has surged. Advancements in imaging technology and increased healthcare provider awareness are key factors driving this segment's growth.

• The surgery segment is expected to grow at the fastest CAGR in the global fatty liver treatment market during the forecast period.   

Based on the treatment, the global fatty liver treatment market is divided into pharmacological treatments, surgery, and lifestyle changes. Among these, the surgery segment is expected to grow at the fastest CAGR in the global fatty liver treatment market during the forecast period. Surgical interventions like gastric bypass or sleeve gastrectomy are commonly used to treat non-alcoholic fatty liver disease (NAFLD) in obese patients. These procedures promote weight loss, improve liver fat, inflammation, and fibrosis, and reduce the risk of progression to cirrhosis or liver failure. However, they are typically reserved for high-BMI patients or those at risk for liver-related complications.

Regional Segment Analysis of the Global Fatty Liver Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global fatty liver treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the global fatty liver treatment market over the predicted timeframe. The region is expected to dominate the global fatty liver treatment market due to the high prevalence of NAFLD, rising obesity rates, and lifestyle-related health issues. The region's advanced healthcare infrastructure, strong research and development activities, and major pharmaceutical companies contribute to its dominance.

Asia Pacific is expected to grow at the fastest pace in the global fatty liver treatment market during the forecast period. The region is going to experience the fastest growth in the global fatty liver treatment market due to rising incidences in China and India, lifestyle changes, obesity, and urbanization. Improved healthcare infrastructure, increased liver health awareness, and a focus on preventive measures are also driving demand.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global fatty liver treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Gilead Sciences
• Intercept Pharmaceuticals
• Novo Nordisk
• Genfit
• Echosens
• AbbVie
• Bristol-Myers Squibb
• Merck & Co.
• Pfizer
• Takeda Pharmaceutical Company
• Sanofi
• Eli Lilly and Company
• Amgen
• Bayer AG
• AstraZeneca
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In March 2024, The U.S. FDA approved Rezdiffra (resmetirom) for treating adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, in combination with diet and exercise.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global fatty liver treatment market based on the below-mentioned segments: 

Global Fatty Liver Treatment Market, By Type

• Non-Alcoholic Fatty Liver Disease
• Non-Alcoholic Steatohepatitis
• Alcoholic Fatty Liver Disease

Global Fatty Liver Treatment Market, By Diagnosis

• Imaging
• Liver Biopsy
• Blood Tests

Global Fatty Liver Treatment Market, By Treatment

• Pharmacological Treatments
• Surgery
• Lifestyle Changes

Global Fatty Liver Treatment Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa